A population-based study on the association between acute renal failure (ARF) and the duration of polypharmacy

BMC Nephrology

Table 2 Stepwise logistic regression of the duration of polypharmacy and ARF

	$\hat{β}$	SE( $\hat{β}$ )	Adjusted odds ratio	p-value
Duration of polypharmacy: Less than 30 days*
31- 90 days	0.28	0.03	1.33	<0.001
91 – 180 days	0.50	0.03	1.65	<0.001
Over 181 days	0.55	0.03	1.74	<0.001
Gender:Female*
Male	0.28	0.02	1.32	<0.001
Age:0-18 years old *
19-64 years old	1.86	0.08	6.40	<0.001
65-79 years old	2.19	0.08	8.93	<0.001
Over 80 years old	2.67	0.08	14.46	<0.001
ICUs	1.48	0.02	4.37	<0.001
Comorbidity
ASHD	−0.23	0.02	0.80	<0.001
CHF	0.67	0.03	1.95	<0.001
CVA/TIA	0.21	0.02	1.24	<0.001
PVD	0.14	0.04	1.15	0.001
Other cardiac	0.08	0.03	1.09	0.006
COPD	−0.10	0.02	0.91	<0.001
GI	0.30	0.02	1.36	<0.001
Liver disease	0.15	0.02	1.16	<0.001
Cancer	0.65	0.02	1.92	<0.001
Diabetes	0.46	0.02	1.58	<0.001
Site of operation
Nervous system	−0.82	0.07	0.44	<0.001
Endocrine system	−2.25	0.26	0.11	<0.001
Nose, mouth and pharynx	−0.58	0.14	0.56	<0.001
Respiratory system	−0.30	0.03	0.75	<0.001
Cardiovascular system	0.38	0.02	1.47	<0.001
Digestive system	0.26	0.02	1.30	<0.001
Urinary system	−0.21	0.03	0.81	<0.001
Male genital organs	−1.38	0.54	0.25	0.010
Female genital organs	−2.63	1.01	0.07	0.009
Musculoskeletal system	−0.15	0.06	0.86	0.007
Integumentary system	0.11	0.05	1.12	0.039
Miscellaneous diagnostic and therapeutic procedures	0.35	0.02	1.42	<0.001

ISSN: 1471-2369